Authors
Latest:
Improving Access to Bone Marrow Transplant and Cellular TherapiesStem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.
Latest:
Improving Access to Trials and Reducing Health Disparities at Rutgers Cancer InstituteMariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss some specific practices and policies that have been most effective at their institution and how these may be adopted by other practices.
Latest:
Phase 3 NATALEE Study Assesses Ribociclib Plus ET in Early Breast CancerDennis J. Slamon, MD, discusses the rationale of the phase 3 NATALEE trial and ribociclib for the treatment of patients with HR+/HER2- early breast cancer.
Latest:
Closing Reflections on Evolving Practices for Bispecific AdministrationBrooke Peters, PharmD, BCOP, offers a closing reflection on the transition from inpatient to outpatient treatment of bispecific antibodies.
Latest:
Exploring the Key Takeaways from the CARTITUDE-2 Trial in Multiple MyelomaMounzer Agha, MD, discusses the phase 2 CARTITUDE-2 trial looking at ciltacabtagene autoleucel in patients with multiple myeloma.
Latest:
CHRYSALIS Study Shows Potential of Amivantamab/Lazertinib in EGFRm NSCLCSe-Hoon Lee, MD, an oncologist at the Samsung Medical Center in Seoul, Korea, discusses his focus of research in the lung cancer space, including the phase 1 CHRYSALIS study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Latest:
Improving Access to Trials and Reducing Health Disparities at Rutgers Cancer InstituteMariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss some specific practices and policies that have been most effective at their institution and how these may be adopted by other practices.
Latest:
Precision Medicine Implemented in the Community Oncology SettingTechnology plays a pivotal role in enhancing precision medicine within cancer care.
Latest:
Overcoming Barriers in Cancer Clinical Trials: A Path Forward for Better Patient CareClinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.
Latest:
Breast Cancer Awareness Month: Recent Developments and Future Directions for Immunotherapy TreatmentMargaret E. Gatti-Mays, MD, MPH, FACP, evaluates the evolution of immunotherapy in cases of breast cancer for Breast Cancer Awareness Month.
Latest:
Choosing BTK Inhibitors Versus Venetoclax as First-Line CLL TherapyNilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.
Latest:
JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCCThe potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Latest:
Making Treatment and Screening Decisions for Patients With Prostate CancerHagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.
Latest:
Shouse Covers the Future of Lymphoma Therapy With Bispecific AntibodiesGeoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.
Latest:
Developments in Targeted Therapies and Liquid BiopsiesDavid L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.
Latest:
Tisa-Cel Shows Efficacy and Durability in R/R Follicular LymphomaStephen Schuster, MD, discusses findings from follow-up of the phase 2 ELARA study presented at the 2023 ASH Annual Meeting.
Latest:
Larotrectinib Does Not Increase Risk of Fractures for Thyroid CancerTheodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.
Latest:
Nivolumab Plus Chemo Improves OS in Chinese Patients With Advanced Gastric/GEJ CancerThe phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Latest:
Rise in Prostate Cancer Cases Contributes to Challenges in CareMurugesan Manoharan, MD, FRACS, offers observations about prostate cancer care at Miami Cancer Institute.
Latest:
Exploring Preliminary Results of Ibrutinib and Fludarabine in CLLChristopher Pleyer, MD, discusses the phase 2 study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Latest:
Advice for Managing Adverse Events of Sacituzumab Govitecan in TNBCRuta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.
Latest:
Neoadjuvant Immunotherapy Expands Its Reach in Metastatic MelanomaA number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.
Latest:
Targeted Therapy Options for Gastric/GEJ Cancers ExpandRonan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.
Latest:
Jurczak on BTK Inhibitors and the Future of B-Cell Lymphoma TherapyWojciech Jurczak, MD, PhD, discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders.
Latest:
ALPINE Trial Shows Zanubrutinib Outperforms Ibrutinib in CLL/SLLHabte Yimer, MD, provides an overview of the ALPINE trial of zanubrutinib vs ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Prior Pluvicto Shortage Led to Long Waiting Lists for Patients With mCRPCRoby Thomas, MD, discusses the shortage of lutetium Lu 177 vipivotide tetraxetan, and how it had affected patients with metastatic castration-resistant prostate cancer being treated at UPMC Hillman Cancer Center.
Latest:
The Future of Research in PEComasThe panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
